JP2009541373A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541373A5
JP2009541373A5 JP2009516901A JP2009516901A JP2009541373A5 JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5 JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5
Authority
JP
Japan
Prior art keywords
vaccine
adjuvant
peptide
protein
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541373A (ja
JP5165681B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2007/000312 external-priority patent/WO2008000261A2/en
Publication of JP2009541373A publication Critical patent/JP2009541373A/ja
Publication of JP2009541373A5 publication Critical patent/JP2009541373A5/ja
Application granted granted Critical
Publication of JP5165681B2 publication Critical patent/JP5165681B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516901A 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大 Expired - Fee Related JP5165681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600861 2006-06-28
DKPA200600861 2006-06-28
PCT/DK2007/000312 WO2008000261A2 (en) 2006-06-28 2007-06-26 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Publications (3)

Publication Number Publication Date
JP2009541373A JP2009541373A (ja) 2009-11-26
JP2009541373A5 true JP2009541373A5 (enExample) 2010-07-29
JP5165681B2 JP5165681B2 (ja) 2013-03-21

Family

ID=38845996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516901A Expired - Fee Related JP5165681B2 (ja) 2006-06-28 2007-06-26 タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大

Country Status (11)

Country Link
US (2) US8105614B2 (enExample)
EP (3) EP2040745B1 (enExample)
JP (1) JP5165681B2 (enExample)
KR (1) KR20090024292A (enExample)
AU (1) AU2007264205B2 (enExample)
BR (1) BRPI0713978A2 (enExample)
CA (1) CA2654271A1 (enExample)
DK (1) DK2040745T3 (enExample)
ES (1) ES2400531T3 (enExample)
RU (1) RU2490024C2 (enExample)
WO (1) WO2008000261A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
EP2160198A2 (en) * 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
SI2167124T1 (sl) * 2007-06-29 2012-12-31 Statens Serum Institut Uporaba monomikolil glicerola (mmg) kot adjuvansa
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2358386B1 (en) * 2008-11-28 2016-11-02 Statens Serum Institut Optimized influenza vaccines
MX2011011186A (es) * 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
CA3002946C (en) * 2009-11-05 2021-11-02 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
WO2011063133A1 (en) * 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
JP6758185B2 (ja) * 2013-12-13 2020-09-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルチエピトープｔａｒｐペプチドワクチンおよびその使用
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN117064854A (zh) * 2023-08-14 2023-11-17 广州谦毅生物医药有限公司 一种卡瓦脂质体的制备技术

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
ATE236981T1 (de) * 1993-11-04 2003-04-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
JP4987704B2 (ja) 2004-07-07 2012-07-25 スタテンス セールム インスティトゥート 糖脂質を用いた、脂質系アジュバント製剤を安定化する組成物及び方法
FR2873467A1 (fr) 2004-07-26 2006-01-27 Proton World Internatinal Nv Enregistrement d'une cle dans un circuit integre
CA2634888C (en) * 2006-01-26 2016-06-21 Pfizer Products Inc. Novel glycolipid adjuvant compositions
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides

Similar Documents

Publication Publication Date Title
JP2009541373A5 (enExample)
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
US12070498B2 (en) Conjugate vaccine targeting a disease-causing biological protein
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
CN103747797B (zh) 脂质体制剂
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
EP2200638B1 (en) Compositions for the transfection of cells
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
JP2011512123A5 (enExample)
RU2009102389A (ru) Расширение спектра клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
JP2011518179A5 (enExample)
JP2003531128A (ja) 修飾ペプチドを含む医薬調製物
JP6158097B2 (ja) 炎症を抑制するためのペプチド
CN102088992B (zh) 肽基二酰基甘油酯
JP7050807B2 (ja) 新規ペプチドベースのｐｃｓｋ９ワクチン
JPWO2012147805A1 (ja) 脳移行性機能性核酸及びその利用
CN119818665A (zh) 新型发热伴血小板减少综合征病毒疫苗
JP2008531463A5 (enExample)
KR20090009839A (ko) 면역조절 올리고펩티드
RU2003110420A (ru) Дифференцирование gnrh-i и gnrh-ii
JPWO2000051634A1 (ja) 脂肪酸を構成成分とするワクチン製剤
CN102178926A (zh) 预防或治疗肝损伤的肽
Lundstrom Novel approach for vaccine delivery using mRNA lipid nanoparticles for in vivo production of monoclonal antibodies
CN121693514A (zh) 含有Braf肽两亲分子的组合物及其使用方法
Sanderson et al. New Generation of Adjuvants for Protection Against Disease and to Combat Bioterrorism